&w=1920&resize=1920,1267&ssl=1 "How to support the poor? Jantric drugs? But no compromise with quality …")
Today, we are living in such a age when the cost of health care is growing rapidly. In such a situation, Generic medicines provide a durable and cost-effective or cheaper solution without compromising the quality of the treatment. Adopting genetic drugs for those people who cannot buy expensive medicines in India can be greatly relief.
What is Jantric medicine?
Generic medicines are bioequivalent compatories of brand medicines whose active elements, doos type and medicinal effects are the same. They are marketed after the prescription of the original Branded medicine and other manufacturers can produce it.
Generic medicines may be useful in long illnesses
The original brand drugs are very expensive, and may fall heavily on repeated buying pockets. The biggest advantage of the genric drugs is their reasonable price. Many studies have proved that the value of them are less than 50 to 90 per cent than the real branded drugs.
Most patients with diabetes, high blood pressure like thyroid diseases or heart disease, has to spend a lot of medicines every month. In a study published in the Asian Journal of Pharmaceutical and Clinical Research in 2024, the average daily price of Branded Anti-diabetes was ₹ 12.10, while a similar genetic drug was priced at 12.10 per day. This is almost the monthly savings of ₹ 480, which is enough for a long-term treatment.
Generic drug market
In addition, the market of the Indian genric drugs are expected to be a 24.91 billion in 2024 and a compounded annual growth (CAGR) of 6.02% between 2023 and 2030. These figures show that Jantric medicines will complete the country’s healthcare requirements.
The quality of genric drugs is a major concern. But regulatory organizations such as Central Drugs Control Organization (CDSCO) ensure that all the generic drugs in India fulfill the strict quality standards. Such drugs have to be strict assessment in investigation into organic equality, security and effectiveness before issuing the public.